Cargando…
免疫检查点抑制剂治疗EGFR突变非小细胞肺癌的研究进展
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105349/ https://www.ncbi.nlm.nih.gov/pubmed/30172273 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |